Back to Search
Start Over
Multicenter Comparison of Molecular Tumor Boards in The Netherlands
- Source :
- Oncologist, 26(8), E1347-E1358. AlphaMed Press, Koopman, B, Groen, H J M, Ligtenberg, M J L, Grünberg, K, Monkhorst, K, de Langen, A J, Boelens, M C, Paats, M S, von der Thüsen, J H, Dinjens, W N M, Solleveld, N, van Wezel, T, Gelderblom, H, Hendriks, L E, Speel, E J M, Theunissen, T E, Kroeze, L I, Mehra, N, Piet, B, van der Wekken, A J, Ter Elst, A, Timens, W, Willems, S M, Meijers, R W J, de Leng, W W J, van Lindert, A S R, Radonic, T, Hashemi, S M S, Heideman, D A M, Schuuring, E & van Kempen, L C 2021, ' Multicenter comparison of Molecular Tumor Boards in the Netherlands : definition, composition, methods and targeted therapy recommendations ', The Oncologist, vol. 26, no. 8, pp. e1347-e1358 . https://doi.org/10.1002/onco.13580, The Oncologist, 26(8), e1347-e1358. AlphaMed Press, The Oncologist, 26(8). ALPHAMED PRESS, Oncologist, 26, 8, pp. e1347-e1358, Oncologist, 26(8), e1347-e1358. AlphaMed Press, The Oncologist, 26(8), e1347-e1358. WILEY, Oncologist, 26, e1347-e1358, The Oncologist
- Publication Year :
- 2020
-
Abstract
- Background Molecular tumor boards (MTBs) provide rational, genomics‐driven, patient‐tailored treatment recommendations. Worldwide, MTBs differ in terms of scope, composition, methods, and recommendations. This study aimed to assess differences in methods and agreement in treatment recommendations among MTBs from tertiary cancer referral centers in The Netherlands. Materials and Methods MTBs from all tertiary cancer referral centers in The Netherlands were invited to participate. A survey assessing scope, value, logistics, composition, decision‐making method, reporting, and registration of the MTBs was completed through on‐site interviews with members from each MTB. Targeted therapy recommendations were compared using 10 anonymized cases. Participating MTBs were asked to provide a treatment recommendation in accordance with their own methods. Agreement was based on which molecular alteration(s) was considered actionable with the next line of targeted therapy. Results Interviews with 24 members of eight MTBs revealed that all participating MTBs focused on rare or complex mutational cancer profiles, operated independently of cancer type–specific multidisciplinary teams, and consisted of at least (thoracic and/or medical) oncologists, pathologists, and clinical scientists in molecular pathology. Differences were the types of cancer discussed and the methods used to achieve a recommendation. Nevertheless, agreement among MTB recommendations, based on identified actionable molecular alteration(s), was high for the 10 evaluated cases (86%). Conclusion MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational cancer profiles. We propose a “Dutch MTB model” for an optimal, collaborative, and nationally aligned MTB workflow. Implications for Practice Interpretation of genomic analyses for optimal choice of target therapy for patients with cancer is becoming increasingly complex. A molecular tumor board (MTB) supports oncologists in rationalizing therapy options. However, there is no consensus on the most optimal setup for an MTB, which can affect the quality of recommendations. This study reveals that the eight MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational profiles. The Dutch MTB model is based on a collaborative and nationally aligned workflow with interinstitutional collaboration and data sharing.<br />Worldwide, molecular tumor boards (MTBs) differ in terms of scope, composition, methods, and recommendations. This article assesses differences in methods and agreement in treatment recommendations among MTBs from tertiary cancer referral centers in The Netherlands.
- Subjects :
- 0301 basic medicine
Cancer Research
medicine.medical_specialty
Cancer Diagnostics and Molecular Pathology
Referral
Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]
medicine.medical_treatment
Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]
Molecular tumor board
Targeted therapy
03 medical and health sciences
0302 clinical medicine
SDG 3 - Good Health and Well-being
Multidisciplinary approach
Neoplasms
Physicians
Rare mutations
Tumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]
Molecular diagnostics
Humans
Medicine
Tumor board
Target therapy
Pathology, Molecular
Composition methods
Netherlands
Multidisciplinary
business.industry
Cancer
medicine.disease
CANCER
PATHOLOGY
030104 developmental biology
Workflow
Oncology
Urological cancers Radboud Institute for Health Sciences [Radboudumc 15]
030220 oncology & carcinogenesis
Family medicine
business
Decision making
GENOMICS
Subjects
Details
- Language :
- English
- ISSN :
- 10837159
- Volume :
- 26
- Issue :
- 8
- Database :
- OpenAIRE
- Journal :
- Oncologist
- Accession number :
- edsair.doi.dedup.....b79685fe23b5073d9c4cfdf7af2ceb19